Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sergio J. Baratta"'
Autor:
Mateo Iwanowski, Jorge A. Bilbao, José M. Bonorino, Horacio E. Fernández, Renzo E. Melchiori, Nicolás A. Torres, Ricardo A. Costantini, José C. Santucci, Santiago N. Márquez Herrero, Pablo M. Rubio, Emilia M. Spaini, Guido M. García Juárez, Mateo Bivort Haiek, Guillermo N. Vaccarino, Sergio J. Baratta
Publikováno v:
REC: Interventional Cardiology, Vol 4, Iss 3, Pp 199-206 (2022)
RESUMEN Introducción y objetivos: Los pacientes con tromboembolia pulmonar (TEP) aguda hemodinámicamente inestables son candidatos para recibir trombolisis sistémica (TS); sin embargo, el tratamiento guiado por catéter (TGC) y la trombectomía qu
Externí odkaz:
https://doaj.org/article/5aa930c2cab2418ca2b9386baa0ee24b
Autor:
Mateo Iwanowski, Jorge A. Bilbao, José M. Bonorino, Horacio E. Fernández, Renzo E. Melchiori, Nicolás A. Torres, Ricardo A. Costantini, José C. Santucci, Santiago N. Márquez Herrero, Pablo M. Rubio, Emilia M. Spaini, Guido M. García Juárez, Mateo Bivort Haiek, Guillermo N. Vaccarino, Sergio J. Baratta
Publikováno v:
REC: Interventional Cardiology (English Ed.), Vol 4, Iss 3, Pp 199-206 (2022)
Abstract Introduction and objectives: Hemodynamically unstable patients with acute pulmonary embolism (PE) are eligible for systemic thrombolysis (ST). However, catheter-directed therapy (CDT) and surgical thrombectomy (SUT) can also be considered wi
Externí odkaz:
https://doaj.org/article/dec4e951bfcc4e809f90f71fa297056d
Autor:
Andrés N. Atamañuk, Diego F. Litewka, Sergio J. Baratta, Ignacio M. Seropian, Graciela Perez Prados, Miguel O. Payaslian, Juan P. Ortiz Fragola, Pilar Escribano Subias
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-6 (2019)
Abstract Background There is little information about vitamin D (Vit D) deficiency in patients with pulmonary hypertension (PH). The objective of this study was: 1) compare Vit D levels between patients with PH, left ventricular failure (LVF) and hea
Externí odkaz:
https://doaj.org/article/4d6921e7e165424e82a6f2db0a9f9b2b
Publikováno v:
Medicina. 82(6)
Advances in knowledge incorporated in the last decade have modified the treatment paradigm in most of the malignant hematological diseases. In particular, the introduction of Bruton tyrosine kinase inhibitors (BTKi) and other target drugs together wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1a5440623dcff503ea39bc5c0f0a575a
https://pubmed.ncbi.nlm.nih.gov/36571531
https://pubmed.ncbi.nlm.nih.gov/36571531
Autor:
Farrukh T. Awan, Daniel Addison, Feras Alfraih, Sergio J. Baratta, Rodrigo Noronha Campos, María Silvana Cugliari, Yeow Tee Goh, Valery Alexandrovich Ionin, Stefanie Mundnich, Aaron L. Sverdlov, Constantine Tam, Loïc Ysebaert
Publikováno v:
Blood advances. 6(18)
Bruton’s tyrosine kinase inhibitors (BTKis) have altered the treatment landscape for chronic lymphocytic leukemia (CLL) by offering effective and well-tolerated therapeutic options. However, since the approval of ibrutinib, concern has risen regard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea6276db37ce9f563e92a6f6379d86b1
https://pubmed.ncbi.nlm.nih.gov/35790105
https://pubmed.ncbi.nlm.nih.gov/35790105